Straits Times Index
3,305.13 +1.94 (+0.06%) Nikkei
38,835.10 +599.03 (+1.57%) Hang Seng
18,488.21 -90.09 (-0.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,547.19 -813.41 (-1.26%) CMC Crypto 200
1,367.40 +2.27 (+0.17%)
Armata Pharmaceuticals, Inc. (TG1N.F)
| Previous close | 2.2800 |
| Open | 2.2600 |
| Bid | 2.3600 x N/A |
| Ask | 2.6200 x N/A |
| Day's range | 2.2600 - 2.2600 |
| 52-week range | 0.9250 - 4.4600 |
| Volume | |
| Avg. volume | 145 |
| Market cap | 84.358M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.67 |
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023, and provided a corporate update.
- PR Newswire
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
- PR Newswire
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.
